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We thank Marshall et al for the interest in and comments on our SB4 Phase III study publication and 
subsequent correspondence regarding immunogenicity.[1-3]  
Anti-drug antibody (ADA) incidence in clinical trials varies widely, and is dependent on both the 
ADA assay method and sampling schedule. In the SB4 Phase III study[1],  the MSD 
electrochemiluminescence (ECL) bridging assay (Meso Scale Discovery, MD, USA) with acid 
dissociation which is considered to be a sensitive assay was used. ADAs and neutralising antibodies 
(NAbs) were measured earlier and more frequently in our study (weeks 0, 2, 4, 8, 12, 16, 24, and 52) 
than previous studies with etanercept reference product (ETN). Most of the ADAs in the ETN 
treatment group were detected at weeks 4-8 when ADAs were not usually measured in the previous 
studies with ETN [4-10], partially accounting for the apparent discrepancy of ADA incidence between 
this study and the previously published clinical studies. In addition, advances in assay technology 
over time could contribute to the higher ADA incidence [1 11-16] (in RA patients approximately 
6%[17] vs. 13%[1] for etanercept, 8%[18] vs. 48%[13] for infliximab, and 5.5%[19] vs. 38%[20] for 
adalimumab in historical studies vs. recent biosimilar studies, respectively). 
We reported significantly lower incidence of ADA in SB4 (0.7%) compared to ETN (13.1%) up to 
week 24 (p<0.001).[1] The CHMP conclusion about SB4 was that “the favourable immunogenicity 
profile of SB4 compared to ETN was uncertain because of the low drug tolerance of the ADA assay 
that led to a low sensitivity and a potential bias”.[21] In regards to inconsistent conclusion between 
EPAR and this publication, we would like to point out the following.  
As the presence of the drug could have increased false negative ADA results in SB4 and ETN, 
immunogenicity was re-assessed using the improved assay in terms of drug interference[22] in a 
subset of patients whose serum drug concentrations were measured (pharmacokinetic [PK] population; 
41 patients in SB4 and 38 patients in ETN). This assay could detect 500 ng/mL anti-SB4 and anti-
ETN antibodies in the presence of 10 μg/mL of etanercept. The serum concentrations of etanercept in 
our study ranged from 0 μg/mL to 6.356 μg/mL, and thus the amended ADA assay was more tolerable 
in detecting ADA in terms of drug interference. With the amended ADA assay, the incidence of ADA 
up to week 24 in the PK population was 2.4% (1/41) in SB4 treatment group and 21.1% (8/38) in the 
ETN treatment group (results to be published). 
In the Phase I study with SB4[23],  immunogenicity was measured 28 days after a single injection of 
etanercept when the serum concentration of etanercept (ranged from 0 ng/mL to 238.97 ng/mL) was 
far below the drug tolerance level of ADA assay used in MSD ECL assay, which could detect 
500 ng/mL of anti-SB4 and anti-ETN antibodies in the presence of 2-3 μg/mL of etanercept, i.e. all 
ADAs were measured without any drug interference.[24] Consistent with the Phase III results, the 
ADA incidence was significantly lower in SB4 (0.0%, 0/45) compared to EU-ETN (15.6%, 7/45, p = 
0.006 compared with SB4) or US-ETN (22.7%, 10/44, p < 0.001 compared with SB4).[23] 
We  hope that the above additional information allow the readers of the Annals of the Rheumatic 
Diseases to make well-informed decisions, and to be re-assured that the immunogenicity data in our 
publication is valid and reliable.  
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